Who are in the management team of Mirati Therapeutics, Inc.?

Jun 22 2025 10:23 PM IST
share
Share Via
As of March 2022, the management team of Mirati Therapeutics, Inc. includes Chairman Faheem Hasnain, CEO Dr. Charles Baum, and several independent directors: Dr. Bruce Carter, Dr. Julie Cherrington, Mr. Aaron Davis, Dr. Henry Fuchs, and Mr. Michael Grey. They oversee the company's strategic direction and operations.
As of March 2022, the management team of Mirati Therapeutics, Inc. includes the following individuals:

- Mr. Faheem Hasnain, Chairman of the Board
- Dr. Charles Baum, President, Chief Executive Officer, and Director
- Dr. Bruce Carter, Independent Director
- Dr. Julie Cherrington, Independent Director
- Mr. Aaron Davis, Independent Director
- Dr. Henry Fuchs, Independent Director
- Mr. Michael Grey, Independent Director

This team is responsible for guiding the strategic direction and operations of the company.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is Mirati Therapeutics, Inc. overvalued or undervalued?
Jun 25 2025 08:44 AM IST
share
Share Via
What does Mirati Therapeutics, Inc. do?
Jun 22 2025 06:29 PM IST
share
Share Via
Most Read